Table 2 Incremental effectiveness and costs of adjuvant S-1 therapy (discount rate: 3% for both effectiveness and costs)
From: Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1
Period | S-1 therapy | Surgery alone | Incremental effectiveness and costs (95% CI) |
|---|---|---|---|
Effectiveness | |||
| Â | QALYs | Â | Â |
5-year observation | 3.11 | 2.84 | 0.27 (0.11 – 0.42) |
10-year follow-up | 5.08 | 4.45 | 0.64 (0.28 – 0.99) |
Over lifetime | 8.65 | 7.41 | 1.24 (0.48 – 1.96) |
| Â | Costs ($) | Â | Â |
5-year observation | 10,802 | 7,408 | 3,389 (2,616 – 4,174) |
10-year follow-up | 12,110 | 8,523 | 3,585 (2,750 – 4,411) |
Over lifetime | 13,057 | 9,346 | 3,722 (2,911 – 4,512) |
Incremental cost-effectiveness ratio | |||
| Â | Cost ($) per QALY gained | (95% CI) | |
5-year observation | 12,716 | (6,428 – 34,018) | |
10-year follow-up | 5,608 | (2,855 – 14,569) | |
Over lifetime | 3,016 | (1,441 – 8,840) | |